Pyogenic granuloma as a cutaneous adverse effect of vemurafenib

New England Journal of Medicine

Volumn 371, Issue 13, 2014, Pages 1265-1267

  Sammut, Stephen John ^a   Tomson, Nevianna ^b   Corrie, Pippa ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b WEST SUFFOLK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GLUTAMIC ACID; VALINE; VEMURAFENIB; INDOLE DERIVATIVE; SULFONAMIDE;

ADULT; AXILLARY LYMPH NODE; BRAF GENE; CANCER SIZE; CANCER STAGING; CASE REPORT; DRUG ERUPTION; DRUG WITHDRAWAL; EXCISION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; LETTER; LYMPHADENOPATHY; MALE; MELANOMA; METASTASIS POTENTIAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PYOGENIC GRANULOMA; RETREATMENT; SKIN GRAFT; SKIN SURGERY; TREATMENT RESPONSE; VASCULAR LESION; AGED; CHEMICALLY INDUCED DISORDER; NOSE; PATHOLOGY; SKIN TUMOR;

AGED; DRUG ERUPTIONS; GRANULOMA, PYOGENIC; HUMANS; INDOLES; MALE; MELANOMA; NOSE; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84907424693     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407683     Document Type: Letter

References (5)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
2. Anforth R, Fernandez-Peñas P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013;14(1):e11-e18.
3. Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KSM. Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 2013;10:390-9.
4. Arbiser JL, Weiss SW, Arbiser ZK, et al. Differential expression of active mitogen-activated protein kinase in cutaneous endothelial neoplasms: implications for biologic behavior and response to therapy. J Am Acad Dermatol 2001;44:193-7.
5. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.